Achieve Life Sciences (ACHV) Profit After Tax (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Profit After Tax of -$10.2 million in Q1 2026, up 30.43% on a QoQ basis from -$14.7 million in Q4 2025, and up 20.48% year-over-year from -$8.5 million in Q1 2025.
Achieve Life Sciences (ACHV) Profit After Tax (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Profit After Tax across 17 years of filings, most recently posting -$10.2 million for Q1 2026.
- Quarterly Profit After Tax rose 20.48% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.0 million (down 12.78% YoY) and the FY2025 annual result came in at -$54.6 million, down 37.21% from the prior year.
- Profit After Tax rose to -$10.2 million in Q1 2026, from -$14.7 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$5.5 million in Q4 2023 and troughed at -$14.7 million in Q4 2025.
- A 5-year average of -$10.4 million and a median of -$10.5 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 51.25% — and 2024, when it tumbled 125.11%.
- Tracing ACHV's Profit After Tax over 5 years: stood at -$11.2 million in 2022, then surged by 51.25% to -$5.5 million in 2023, then sank by 125.11% to -$12.3 million in 2024, then dropped by 18.94% to -$14.7 million in 2025, then surged by 30.43% to -$10.2 million in 2026.
- Business Quant data shows ACHV's Profit After Tax at -$10.2 million in Q1 2026, -$14.7 million in Q4 2025, and -$14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.74 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -10.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.20 Mn |
| Dec 31, 2025 | -14.66 Mn |
| Sep 30, 2025 | -14.44 Mn |
| Jun 30, 2025 | -12.72 Mn |
| Mar 31, 2025 | -12.83 Mn |
| Dec 31, 2024 | -12.33 Mn |
| Sep 30, 2024 | -12.51 Mn |
| Jun 30, 2024 | -8.46 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Dec 31, 2023 | -5.48 Mn |
| Sep 30, 2023 | -7.11 Mn |
| Jun 30, 2023 | -8.24 Mn |
| Mar 31, 2023 | -8.99 Mn |
| Dec 31, 2022 | -11.23 Mn |
| Sep 30, 2022 | -13.08 Mn |
| Jun 30, 2022 | -10.47 Mn |
| Mar 31, 2022 | -7.57 Mn |
| Dec 31, 2021 | -7.15 Mn |
| Sep 30, 2021 | -6.69 Mn |
| Jun 30, 2021 | -11.31 Mn |